CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF Signaling
Open Access
- 1 May 2006
- journal article
- Published by Elsevier BV in Neoplasia
- Vol. 8 (5), 394-401
- https://doi.org/10.1593/neo.05820
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Rapamycin Inhibits Ezrin-Mediated Metastatic Behavior in a Murine Model of OsteosarcomaCancer Research, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cellsOncogene, 2003
- Rheb promotes cell growth as a component of the insulin/TOR signalling networkNature, 2003
- Rheb is an essential regulator of S6K in controlling cell growth in DrosophilaNature, 2003
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Pediatric genitourinary tumorsCurrent Opinion in Oncology, 2002
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000
- Rapamycin: A novel immunosuppressive macrolideMedicinal Research Reviews, 1994